Sanofi (SNY, Financial) has once again caught the attention of Morgan Stanley, as analyst Sarita Kapila reinstates coverage with an Equal Weight rating and sets a price target of $56. Despite the appealing valuation and anticipated earnings growth for the period between 2025 and 2028 aligning with industry standards, there are existing concerns about the company's profit margins and the momentum of its development pipeline. These factors may contribute to the ongoing discount of Sanofi's stock. Kapila emphasizes that the company's investment potential is heavily reliant on its research and development performance, which currently requires further demonstration of success. This outlook suggests that investors may need to see more concrete results before fully committing.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Sanofi SA (SNY, Financial) is $66.91 with a high estimate of $69.00 and a low estimate of $63.23. The average target implies an upside of 35.52% from the current price of $49.37. More detailed estimate data can be found on the Sanofi SA (SNY) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Sanofi SA's (SNY, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sanofi SA (SNY, Financial) in one year is $59.29, suggesting a upside of 20.09% from the current price of $49.37. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sanofi SA (SNY) Summary page.
